Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis

医学 三阴性乳腺癌 生物标志物 孕酮受体 乳腺癌 雌激素受体 肿瘤科 表皮生长因子受体 癌症研究 人表皮生长因子受体2 癌症 内科学 生物 生物化学
作者
Xingxin Wang,Xuhao Li,Tiantian Dong,Wenyan Yu,Zhixia Jia,Yi Hou,Jiguo Yang,Yuanxiang Liu
出处
期刊:International Journal of Surgery [Wolters Kluwer]
被引量:1
标识
DOI:10.1097/js9.0000000000001799
摘要

Background: Triple-negative breast cancer (TNBC) is defined as breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in cancer tissue. The lack of specific biomarkers makes the diagnosis and prognosis of TNBC challenging. Method: A comprehensive literature review and bibliometric analysis was performed using CiteSpace, VOSviewer and Scimago Graphica. Results: TNBC biomarker research has been growing rapidly in recent years, reflecting the enormous academic interest in TNBC biomarker research. A total of 127 journals published relevant studies and 1749 authors were involved in the field, with developed countries such as the United States, France, and the United Kingdom contributing greatly to the field. Collaborative network analysis found that the research in this field has not yet formed good communication and interaction, and the partnership should be strengthened in the future in order to promote the in-depth development of TNBC biomarker research. Comprehensive analysis of keywords and co-cited literature, etc. found that TNBC biomarker research mainly focuses on immune checkpoint markers, microenvironment-related markers, circulating tumour DNA, metabolic markers, genomics markers and so on. These research hotspots will help to better understand the molecular characteristics and biological processes of TNBC, and provide more accurate biomarkers for its diagnosis, treatment and prognosis. Conclusions: The bibliometric analysis highlighted global trends and key directions in TNBC biomarker research. Future developments in TNBC biomarker research are likely to be in the direction of multi-omics integration, meticulous study of the microenvironment, targeted therapeutic biomarkers, application of liquid biopsy, application of machine learning and artificial intelligence, and individualised therapeutic strategies. Young scholars should learn and collaborate across disciplines, pay attention to new technologies and methods, improve their data analysis skills, and continue to follow up on the latest research trends in order to meet the challenges and opportunities in the field of TNBC biomarkers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er应助艾妮妮采纳,获得10
2秒前
Jason应助a1207732382采纳,获得50
2秒前
ximeng完成签到 ,获得积分10
3秒前
怕黑山柏发布了新的文献求助10
4秒前
小洁完成签到 ,获得积分10
5秒前
5秒前
大个应助sukk采纳,获得10
6秒前
6秒前
xiaobei88完成签到,获得积分10
7秒前
8秒前
研友_VZG7GZ应助白彧采纳,获得10
9秒前
9秒前
密斯特蟹发布了新的文献求助10
9秒前
杨123完成签到,获得积分10
9秒前
10秒前
墨晟蘅发布了新的文献求助30
12秒前
小赵发布了新的文献求助10
12秒前
古雨林发布了新的文献求助10
13秒前
wst1988完成签到,获得积分0
14秒前
molihuakai应助jansorchen采纳,获得10
14秒前
小美完成签到,获得积分10
15秒前
zz应助一二三四采纳,获得10
15秒前
luckydong完成签到 ,获得积分10
15秒前
CipherSage应助YanDongXu采纳,获得10
16秒前
17秒前
杨广明123发布了新的文献求助10
17秒前
feifei驳回了田様应助
17秒前
危机的秋双完成签到 ,获得积分10
18秒前
科研通AI6.1应助密斯特蟹采纳,获得10
19秒前
英俊的铭应助光亮芷天采纳,获得10
19秒前
吉吉完成签到,获得积分10
19秒前
19秒前
顾矜应助开朗的骁采纳,获得10
20秒前
Ruler完成签到,获得积分10
20秒前
20秒前
做科研的小丸子完成签到,获得积分10
20秒前
20秒前
英姑应助小人物采纳,获得10
21秒前
suxiang完成签到,获得积分20
21秒前
吉吉发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6516840
求助须知:如何正确求助?哪些是违规求助? 8309839
关于积分的说明 17763208
捐赠科研通 5619141
什么是DOI,文献DOI怎么找? 2925625
邀请新用户注册赠送积分活动 1902592
关于科研通互助平台的介绍 1763704